Training activity information
Details
Perform the fluid analyses involved in the detection of major organ disease and cancers to laboratory standard operating procedures to include:
- Cyst fluid
- Chylomicrons
- Pleural fluid
Type
Entrustable training activity (ETA)
Evidence requirements
Evidence the activity has been undertaken by the trainee repeatedly, consistently, and effectively over time, in a range of situations. This may include occasions where the trainee has not successfully achieved the outcome of the activity themselves. For example, because it was not appropriate to undertake the task in the circumstances or the trainees recognised their own limitations and sought help or advice to ensure the activity reached an appropriate conclusion.
Reflection at multiple timepoints on the trainee learning journey for this activity.
Considerations
- Local and national training guidelines, including standards and pathways
- Method selection, including assay advantages and limitations, quality parameters, and interference
- Equipment calibration and maintenance
- Quality control; EQA and IQC
- National and international guidelines
Reflective practice guidance
The guidance below is provided to support reflection at different time points, providing you with questions to aid you to reflect for this training activity. They are provided for guidance and should not be considered as a mandatory checklist. Trainees should not be expected to provide answers to each of the guidance questions listed.
Before action
What does success look like?
- Identify what is expected of you in relation to performing analyses on less common bodily fluids (e.g., cyst fluid, pleural fluid, or chylomicrons assessment) according to laboratory SOPs.
- Consider how the learning outcomes apply, specifically in relation to accurately performing the required analyses and contributing to the interpretation of their results.
- Discuss with your training officer to gain clarity of what is expected of you in relation to specific requirements for sample handling, the required tests for each fluid type, and the relevant instrumentation.
What is your prior experience of this activity?
- Think about what you already know about analysing different types of bodily fluids beyond standard blood and urine samples.
- Consider possible challenges you might face during the activity, such as the unique properties of these fluids affecting analysis, specific analytical techniques or alternative tests required (e.g., for chylomicrons), or dealing with limited sample volumes.
- Recognise the scope of your own practice for this activity i.e. know when you will need to seek advice or help, and from whom. You will need to seek advice from your Training Officer when required, for example if a fluid sample exhibits unusual viscosity or colour requiring modification of the analytical process, or if the interpretation suggests a rare malignancy.
- Acknowledge how you feel about working with and analysing these less common sample types.
What do you anticipate you will learn from the experience?
- Consider the specific skills you want to develop, such as adapting analytical techniques to perform measurements on different fluid types (e.g., pleural fluid).
- Identify the specific insights you hope to gain into the clinical significance of analysing these fluids in the context of major organ diseases (e.g., cardiac or renal) and the specific tests performed.
What additional considerations do you need to make?
- Consult actions identified following previous experiences of analysing different types of bodily fluids.
- Identify important information you need to consider before embarking on the activity, such as access to the SOPs for analysing the specified fluids (e.g., Cyst fluid, Pleural fluid), and understanding the specific pre-analytical requirements for each fluid type.
In action
Is anything unexpected occurring?
- Are you noticing anything surprising or different from what you anticipate whilst performing analyses on unique fluid types (e.g., cyst fluid, pleural fluid, chylomicrons assessment)?
- Are you encountering situations such as:
- The viscosity or cellularity of the fluid sample compromises instrument aspiration or analytical methods?
- Limited sample volume restricts the range of required tests, necessitating an immediate decision on test prioritisation?
- An unusual component is observed (e.g., high turbidity suggesting chylomicrons) that requires a specialised analytical technique?
How are you reacting to the unexpected development?
- How is this impacting your actions? For example, are you responding to the situation appropriately? Are you adapting or changing your approach to sample pre-treatment or analytical method selection?
- Consider the steps you are taking in the moment, such as:
- Immediately consulting the SOP for sample pre-treatment (e.g., dilution or centrifugation) for viscous fluids
- Seeking immediate guidance from the lead scientist to determine the necessary prioritisation of tests due to low sample volume
- How are you feeling in that moment? For instance, are you finding it difficult to adapt the analytical technique for a unique fluid type? Is it affecting your confidence in assessing the sample suitability?
What is the conclusion or outcome?
- Identify how you are working within your scope of practice. For example, are you successfully applying techniques to analyse pleural fluid according to SOP? Or are you needing support because a fluid sample suggests a highly unusual pathological presentation (e.g., rare malignancy) requiring specialist interpretation?
- What are you learning as a result of the unexpected development? For example, are you mastering the necessary technical adaptations for analysing different types of bodily fluids? Or gaining insight into the specific clinical significance and required analysis for cyst fluid or chylomicrons assessment?
On action
What happened?
- Begin by summarising the key steps you took when performing analyses on less common bodily fluids (e.g., cyst fluid, pleural fluid, chylomicrons assessment).
- Consider specific events, actions, or interactions which felt important, such as the adaptations made to handle a viscous pleural fluid sample for routine analysis or the specific analytical technique used to assess chylomicrons.
- Include any ‘reflect-in-action’ moments where you had to adapt to the situation as it unfolded, for instance, immediately seeking guidance when faced with limited sample volume, requiring prioritisation of the required tests.
- How did you feel during this experience, e.g., did you feel confident in following the standard protocol for fluid analysis or proceeding with caution due to the unique properties of the sample?
How has this experience contributed to your developing practice?
- Identify what learning you can take from this experience regarding performing specialised fluid analyses. What strengths did you demonstrate, e.g., ability to adapt standard analytical methods to unusual sample matrices?
- What skills and/or knowledge gaps were evident, e.g., unfamiliarity with the specific interpretation criteria for rare analytes in cyst fluid?
- Compare this experience against previous engagement with similar activities – were any previously identified actions for development achieved? Has your practice improved in assessing the suitability of less common samples for routine analysis?
- Identify any challenges you experienced, such as needing to seek advice or clarification on scope of practice regarding interpreting a result from an unusual fluid that suggested a rare malignancy, and how you reacted to this.
What will you take from the experience moving forward?
- Identify the actions or ‘next steps’ you will now take to support the assimilation of what you have learnt, including from any feedback you have received, with regards to improving ability in handling and analysing specialised fluid samples.
- What will you do differently next time you approach analysing an unusual fluid sample, for instance, by proactively checking the sample’s physical characteristics (e.g., viscosity, colour) against the SOP’s expected matrix?
- Do you need to practise any aspect of the activity further, such as reviewing the required tests for specific body fluid types or key learning outcomes related to performing analyses accurately?
Beyond action
Have you revisited the experiences?
- How have your subsequent experiences of handling potentially biohazardous or complex non-routine samples since completing this specific training activity led you to revisit your initial approach or decisions during that activity? For example, how a subsequent analysis of an unusual biopsy fluid forced you to re-evaluate the meticulousness of the infection control and safety protocols you applied during your first attempt at analysing pleural fluid or cyst fluid.
- Considering what you understand about sample matrix effects, specialised test requirements, and the diagnostic utility of esoteric fluid analysis now, were the actions or considerations you identified after your initial reflection on this training activity sufficient? How have you since implemented or adapted improvements in your handling and analytical adaptation for non-routine fluid types based on further learning and experiences? For example, how you proactively reviewed and integrated specific analytical techniques for assessing chylomicrons in turbid samples, demonstrating adaptability in specialised procedures.
- Has discussing analytical challenges with specific fluid types (e.g., viscosity or cell content) or their clinical significance with colleagues, peers, or supervisors changed how you now view your initial experience in this training activity? For example, how professional storytelling with a senior colleague about a case where a sample was rejected due to incorrect collection method for cyst fluid refined your understanding of the critical role of pre-analytical communication.
How have these experiences impacted upon current practice?
- How has the learning from this initial training activity, in combination with subsequent specialised fluid analysis experiences, contributed to your overall confidence and ability in handling diverse and complex sample matrices, particularly in preparing for assessments like Case-Based Discussions (CBDs)? For example, how your accumulated ability in performing specialised analyses (e.g., for cyst fluid or pleural fluid) and managing unusual sample matrices now enables you to confidently discuss the investigation of less common bodily fluids during a CBD assessment.
- How has reflecting back on this specific training activity, combined with everything you’ve learned since, shaped your current approach to handling and analysing non-routine fluid samples? How does this evolved understanding help you identify when something is beyond your scope of practice or requires escalation? For example, how your evolved approach means you now routinely seek advice from the lead scientist or duty biochemist immediately when an unusual fluid sample presents high biohazard risk or when limited sample volume requires prioritisation of tests, recognising this requires senior judgment on patient safety and diagnostic yield.
- Looking holistically at your training journey, how has this initial fluid analysis experience, revisited with your current perspective, contributed to your development in meeting the learning outcomes related to performing biochemical assays and analysing and interpreting biochemical data? For example, how this foundational experience has supported your development in handling non-routine or potentially infectious samples and understanding how diverse sample matrices affect analytical results.
Relevant learning outcomes
| # | Outcome |
|---|---|
| # 1 |
Outcome
Perform biochemical assays involved in the assessment of major organ function and cancer diagnosis and monitoring. |
| # 2 |
Outcome
Analyse and interpret biochemical data generated in the assessment of major organ function and cancer diagnosis and monitoring. |
| # 3 |
Outcome
Evaluate the national guidelines for diagnosis and management of diseases associated with the major organ systems and cancer. |